Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Northway Biotech Enters Manufacturing Agreement with Kaida

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Northway Biotech Enters Manufacturing Agreement with Kaida BioPharma

Together, the companies will produce Kaida’s KAD101 to treat uterine cancer.

By: Rachel Klemovitch

Assistant Editor

Northway Biotech, an end-to-end CDMO, and Kaida BioPharma (Kaida), an early-stage pharma company, have entered into a manufacturing agreement to produce Kaida’s KAD101.

Per the agreement, Northway Biotech will leverage its expertise to develop a robust manufacturing process for KAD101. 

This involves developing analytical methods, optimizing formulation, development, and scaling up of the production process, and manufacturing a cGMP drug substance batch for clinical studies.

KAD101 is a novel biologic that blocks the prolactin receptor to prevent cancer cell growth signals and incite autophagy, initially targeting ovarian cancer. 

The original biologic G129R demonstrated encouraging results in a human clinical study, with all patients showing tumor reduction on the low-dose cohort with a clean safety profile as a daily injectable. 

Kaida has transformed G129R into a bi-weekly injectable (KAD101) and continues to progress the development towards the launch of a Phase 1 study. This study is expected to start Q4 2026/Q1 2027. 

Additionally, Kaida is advancing KAD102, an enhanced pure antagonist of KAD101, to treat uterine cancer.

Craig Pierson, Founder and Chairman of Kaida BioPharma, commented: “We look forward to working closely with the Northway Biotech team to advance our lead product candidate, KAD101, and progress towards providing targeted anti-cancer therapies to address hormone-driven cancers affecting women.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics